线粒体钙离子单向传输抑制剂 Ru265 可提高神经元的兴奋性,并通过脱靶效应减少神经传递。

IF 6.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY British Journal of Pharmacology Pub Date : 2024-05-23 DOI:10.1111/bph.16425
Peng Xu, Sarpras Swain, Robyn J. Novorolsky, Esperanza Garcia, Zhouyang Huang, Terrance P. Snutch, Justin J. Wilson, George S. Robertson, Robert B. Renden
{"title":"线粒体钙离子单向传输抑制剂 Ru265 可提高神经元的兴奋性,并通过脱靶效应减少神经传递。","authors":"Peng Xu,&nbsp;Sarpras Swain,&nbsp;Robyn J. Novorolsky,&nbsp;Esperanza Garcia,&nbsp;Zhouyang Huang,&nbsp;Terrance P. Snutch,&nbsp;Justin J. Wilson,&nbsp;George S. Robertson,&nbsp;Robert B. Renden","doi":"10.1111/bph.16425","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and Purpose</h3>\n \n <p>Excitotoxicity due to mitochondrial calcium (Ca<sup>2+</sup>) overloading can trigger neuronal cell death in a variety of pathologies. Inhibiting the mitochondrial calcium uniporter (MCU) has been proposed as a therapeutic avenue to prevent calcium overloading. Ru265 (ClRu(NH<sub>3</sub>)<sub>4</sub>(μ-N)Ru(NH<sub>3</sub>)<sub>4</sub>Cl]Cl<sub>3</sub>) is a cell-permeable inhibitor of the mitochondrial calcium uniporter (MCU) with nanomolar affinity. Ru265 reduces sensorimotor deficits and neuronal death in models of ischemic stroke. However, the therapeutic use of Ru265 is limited by the induction of seizure-like behaviours.</p>\n </section>\n \n <section>\n \n <h3> Experimental Approach</h3>\n \n <p>We examined the effect of Ru265 on synaptic and neuronal function in acute brain slices and hippocampal neuron cultures derived from mice, in control and where MCU expression was genetically abrogated.</p>\n </section>\n \n <section>\n \n <h3> Key Results</h3>\n \n <p>Ru265 decreased evoked responses from calyx terminals and induced spontaneous action potential firing of both the terminal and postsynaptic principal cell. Recordings of presynaptic Ca<sup>2+</sup> currents suggested that Ru265 blocks the P/Q type channel, confirmed by the inhibition of currents in cells exogenously expressing the P/Q type channel. Measurements of presynaptic K<sup>+</sup> currents further revealed that Ru265 blocked a KCNQ current, leading to increased membrane excitability, underlying spontaneous spiking. Ca<sup>2+</sup> imaging of hippocampal neurons showed that Ru265 increased synchronized, high-amplitude events, recapitulating seizure-like activity seen <i>in vivo</i>. Importantly, MCU ablation did not suppress Ru265-induced increases in neuronal activity and seizures.</p>\n </section>\n \n <section>\n \n <h3> Conclusions and Implications</h3>\n \n <p>Our findings provide a mechanistic explanation for the pro-convulsant effects of Ru265 and suggest counter screening assays based on the measurement of P/Q and KCNQ channel currents to identify safe MCU inhibitors.</p>\n </section>\n </div>","PeriodicalId":9262,"journal":{"name":"British Journal of Pharmacology","volume":null,"pages":null},"PeriodicalIF":6.8000,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309911/pdf/","citationCount":"0","resultStr":"{\"title\":\"The mitochondrial calcium uniporter inhibitor Ru265 increases neuronal excitability and reduces neurotransmission via off-target effects\",\"authors\":\"Peng Xu,&nbsp;Sarpras Swain,&nbsp;Robyn J. Novorolsky,&nbsp;Esperanza Garcia,&nbsp;Zhouyang Huang,&nbsp;Terrance P. Snutch,&nbsp;Justin J. Wilson,&nbsp;George S. Robertson,&nbsp;Robert B. Renden\",\"doi\":\"10.1111/bph.16425\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background and Purpose</h3>\\n \\n <p>Excitotoxicity due to mitochondrial calcium (Ca<sup>2+</sup>) overloading can trigger neuronal cell death in a variety of pathologies. Inhibiting the mitochondrial calcium uniporter (MCU) has been proposed as a therapeutic avenue to prevent calcium overloading. Ru265 (ClRu(NH<sub>3</sub>)<sub>4</sub>(μ-N)Ru(NH<sub>3</sub>)<sub>4</sub>Cl]Cl<sub>3</sub>) is a cell-permeable inhibitor of the mitochondrial calcium uniporter (MCU) with nanomolar affinity. Ru265 reduces sensorimotor deficits and neuronal death in models of ischemic stroke. However, the therapeutic use of Ru265 is limited by the induction of seizure-like behaviours.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Experimental Approach</h3>\\n \\n <p>We examined the effect of Ru265 on synaptic and neuronal function in acute brain slices and hippocampal neuron cultures derived from mice, in control and where MCU expression was genetically abrogated.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Key Results</h3>\\n \\n <p>Ru265 decreased evoked responses from calyx terminals and induced spontaneous action potential firing of both the terminal and postsynaptic principal cell. Recordings of presynaptic Ca<sup>2+</sup> currents suggested that Ru265 blocks the P/Q type channel, confirmed by the inhibition of currents in cells exogenously expressing the P/Q type channel. Measurements of presynaptic K<sup>+</sup> currents further revealed that Ru265 blocked a KCNQ current, leading to increased membrane excitability, underlying spontaneous spiking. Ca<sup>2+</sup> imaging of hippocampal neurons showed that Ru265 increased synchronized, high-amplitude events, recapitulating seizure-like activity seen <i>in vivo</i>. Importantly, MCU ablation did not suppress Ru265-induced increases in neuronal activity and seizures.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions and Implications</h3>\\n \\n <p>Our findings provide a mechanistic explanation for the pro-convulsant effects of Ru265 and suggest counter screening assays based on the measurement of P/Q and KCNQ channel currents to identify safe MCU inhibitors.</p>\\n </section>\\n </div>\",\"PeriodicalId\":9262,\"journal\":{\"name\":\"British Journal of Pharmacology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2024-05-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309911/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Journal of Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/bph.16425\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bph.16425","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:线粒体钙(Ca2+)超载导致的兴奋毒性可在多种病理情况下引发神经细胞死亡。抑制线粒体钙离子单向传输器(MCU)被认为是防止钙离子超载的一种治疗方法。Ru265(ClRu(NH3)4(μ-N)Ru(NH3)4Cl]Cl3)是一种具有纳摩尔亲和力的线粒体钙离子通道抑制剂。Ru265 可减轻缺血性中风模型中的感觉运动障碍和神经元死亡。然而,Ru265 的治疗用途受到了癫痫样行为诱导的限制:实验方法:我们研究了 Ru265 对小鼠急性脑切片和海马神经元培养物中突触和神经元功能的影响:主要结果:Ru265 降低了来自萼终端的诱发反应,并诱发终端和突触后主细胞的自发动作电位发射。对突触前 Ca2+ 电流的记录表明,Ru265 阻断了 P/Q 型通道,外源表达 P/Q 型通道的细胞电流受到抑制也证实了这一点。对突触前 K+ 电流的测量进一步表明,Ru265 阻断了 KCNQ 电流,导致膜兴奋性增加,成为自发尖峰的基础。海马神经元的 Ca2+ 成像显示,Ru265 增加了同步、高振幅事件,再现了体内癫痫发作样活动。重要的是,MCU 消融并不能抑制 Ru265 诱导的神经元活动增加和癫痫发作:我们的研究结果从机理上解释了 Ru265 的促惊厥效应,并提出了基于 P/Q 和 KCNQ 通道电流测量的反筛选试验,以确定安全的 MCU 抑制剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The mitochondrial calcium uniporter inhibitor Ru265 increases neuronal excitability and reduces neurotransmission via off-target effects

Background and Purpose

Excitotoxicity due to mitochondrial calcium (Ca2+) overloading can trigger neuronal cell death in a variety of pathologies. Inhibiting the mitochondrial calcium uniporter (MCU) has been proposed as a therapeutic avenue to prevent calcium overloading. Ru265 (ClRu(NH3)4(μ-N)Ru(NH3)4Cl]Cl3) is a cell-permeable inhibitor of the mitochondrial calcium uniporter (MCU) with nanomolar affinity. Ru265 reduces sensorimotor deficits and neuronal death in models of ischemic stroke. However, the therapeutic use of Ru265 is limited by the induction of seizure-like behaviours.

Experimental Approach

We examined the effect of Ru265 on synaptic and neuronal function in acute brain slices and hippocampal neuron cultures derived from mice, in control and where MCU expression was genetically abrogated.

Key Results

Ru265 decreased evoked responses from calyx terminals and induced spontaneous action potential firing of both the terminal and postsynaptic principal cell. Recordings of presynaptic Ca2+ currents suggested that Ru265 blocks the P/Q type channel, confirmed by the inhibition of currents in cells exogenously expressing the P/Q type channel. Measurements of presynaptic K+ currents further revealed that Ru265 blocked a KCNQ current, leading to increased membrane excitability, underlying spontaneous spiking. Ca2+ imaging of hippocampal neurons showed that Ru265 increased synchronized, high-amplitude events, recapitulating seizure-like activity seen in vivo. Importantly, MCU ablation did not suppress Ru265-induced increases in neuronal activity and seizures.

Conclusions and Implications

Our findings provide a mechanistic explanation for the pro-convulsant effects of Ru265 and suggest counter screening assays based on the measurement of P/Q and KCNQ channel currents to identify safe MCU inhibitors.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
15.40
自引率
12.30%
发文量
270
审稿时长
2.0 months
期刊介绍: The British Journal of Pharmacology (BJP) is a biomedical science journal offering comprehensive international coverage of experimental and translational pharmacology. It publishes original research, authoritative reviews, mini reviews, systematic reviews, meta-analyses, databases, letters to the Editor, and commentaries. Review articles, databases, systematic reviews, and meta-analyses are typically commissioned, but unsolicited contributions are also considered, either as standalone papers or part of themed issues. In addition to basic science research, BJP features translational pharmacology research, including proof-of-concept and early mechanistic studies in humans. While it generally does not publish first-in-man phase I studies or phase IIb, III, or IV studies, exceptions may be made under certain circumstances, particularly if results are combined with preclinical studies.
期刊最新文献
Network medicine and systems pharmacology approaches to predicting adverse drug effects Progress on the development of Class A GPCR‐biased ligands Issue Information An adenosinergic positive feedback loop extends pharmacological cardioprotection duration A p75 neurotrophin receptor‐sparing nerve growth factor protects retinal ganglion cells from neurodegeneration by targeting microglia
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1